Adele M. Gulfo

CIK: 0001647102

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)25 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

NPO

Enpro Inc.

Director

TYRA

Tyra Biosciences, Inc.

Director

NAMS

NewAmsterdam Pharma Co N.V.

Director

Discretionary Trading P&L

Holdings

Transaction History (25 total)

NPO
Enpro Inc.
Sep 16, 2026
Award(A)
Phantom Stock
Direct
1 shares at avg. $287.16-
NPO
Enpro Inc.
Sep 16, 2026
Award(A)
Phantom Stock
Direct
5 shares at avg. $287.16-
NPO
Enpro Inc.
Jun 17, 2026
Award(A)
Phantom Stock
Direct
4 shares at avg. $363.62-
NPO
Enpro Inc.
Jun 17, 2026
Award(A)
Phantom Stock
Direct
0 shares at avg. $363.62-
TYRA
Tyra Biosciences, Inc.
May 28, 2026
Award(A)
Stock Option (Right to Buy)
Direct
13.2K shares-
NPO
Enpro Inc.
Mar 18, 2026
Award(A)
Phantom Stock
Direct
1 shares at avg. $250.59-
NPO
Enpro Inc.
Mar 18, 2026
Award(A)
Phantom Stock
Direct
5 shares at avg. $250.59-
NPO
Enpro Inc.
Feb 12, 2026
Award(A)
Direct
567 shares at avg. $246.91$140K
NAMS
NewAmsterdam Pharma Co N.V.
Jan 7, 2026
Award(A)
Direct
3.4K shares-
NPO
Enpro Inc.
Dec 31, 2025
Award(A)
Phantom Stock
Direct
117 shares at avg. $214.13-
NPO
Enpro Inc.
Dec 17, 2025
Award(A)
Phantom Stock
Direct
6 shares at avg. $205.19-
NPO
Enpro Inc.
Dec 17, 2025
Award(A)
Phantom Stock
Direct
1 shares at avg. $205.19-
NPO
Enpro Inc.
Sep 30, 2025
Award(A)
Phantom Stock
Direct
111 shares at avg. $226.00-
NPO
Enpro Inc.
Sep 17, 2025
Award(A)
Phantom Stock
Direct
0 shares at avg. $217.89-
NPO
Enpro Inc.
Sep 17, 2025
Award(A)
Phantom Stock
Direct
6 shares at avg. $217.89-
NPO
Enpro Inc.
Jun 30, 2025
Award(A)
Phantom Stock
Direct
131 shares at avg. $191.55-
NPO
Enpro Inc.
Jun 18, 2025
Award(A)
Phantom Stock
Direct
7 shares at avg. $185.86-
NPO
Enpro Inc.
Jun 18, 2025
Award(A)
Phantom Stock
Direct
0 shares at avg. $185.86-
NAMS
NewAmsterdam Pharma Co N.V.
Apr 15, 2025
Award(A)
Direct
10.9K shares-
NPO
Enpro Inc.
Mar 31, 2025
Award(A)
Phantom Stock
Direct
155 shares at avg. $161.79-
NPO
Enpro Inc.
Mar 19, 2025
Award(A)
Phantom Stock
Direct
7 shares at avg. $175.76-
NPO
Enpro Inc.
Feb 13, 2025
Award(A)
Phantom Stock
Direct
685 shares at avg. $182.27-
TYRA
Tyra Biosciences, Inc.
Jan 29, 2025
Award(A)
Common Stock (Right to Buy)
Direct
37.2K shares-
NPO
Enpro Inc.
Dec 18, 2024
Award(A)
Phantom Stock
Direct
7 shares at avg. $175.86-
NPO
Enpro Inc.
Sep 18, 2024
Award(A)
Phantom Stock
Direct
8 shares at avg. $156.77-

		Type	Shares	Price		Ownership
Sep 16, 2026	NPO Enpro Inc.	Award(A) Phantom Stock	1	$287.16	-	Direct
Sep 16, 2026	NPO Enpro Inc.	Award(A) Phantom Stock	5	$287.16	-	Direct
Jun 17, 2026	NPO Enpro Inc.	Award(A) Phantom Stock	4	$363.62	-	Direct
Jun 17, 2026	NPO Enpro Inc.	Award(A) Phantom Stock	0	$363.62	-	Direct
May 28, 2026	TYRA Tyra Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	13,160	-	-	Direct
Mar 18, 2026	NPO Enpro Inc.	Award(A) Phantom Stock	1	$250.59	-	Direct
Mar 18, 2026	NPO Enpro Inc.	Award(A) Phantom Stock	5	$250.59	-	Direct
Feb 12, 2026	NPO Enpro Inc.	Award(A)	567	$246.91	$139,998	Direct
Jan 7, 2026	NAMS NewAmsterdam Pharma Co N.V.	Award(A)	3,400	-	$0	Direct
Dec 31, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	117	$214.13	-	Direct
Dec 17, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	6	$205.19	-	Direct
Dec 17, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	1	$205.19	-	Direct
Sep 30, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	111	$226.00	-	Direct
Sep 17, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	0	$217.89	-	Direct
Sep 17, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	6	$217.89	-	Direct
Jun 30, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	131	$191.55	-	Direct
Jun 18, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	7	$185.86	-	Direct
Jun 18, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	0	$185.86	-	Direct
Apr 15, 2025	NAMS NewAmsterdam Pharma Co N.V.	Award(A)	10,860	-	-	Direct
Mar 31, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	155	$161.79	-	Direct
Mar 19, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	7	$175.76	-	Direct
Feb 13, 2025	NPO Enpro Inc.	Award(A) Phantom Stock	685	$182.27	-	Direct
Jan 29, 2025	TYRA Tyra Biosciences, Inc.	Award(A) Common Stock (Right to Buy)	37,200	-	-	Direct
Dec 18, 2024	NPO Enpro Inc.	Award(A) Phantom Stock	7	$175.86	-	Direct
Sep 18, 2024	NPO Enpro Inc.	Award(A) Phantom Stock	8	$156.77	-	Direct

1-25 of 25 transactions

About Gulfo Adele M.

Gulfo Adele M. (SEC CIK 0001647102) files insider reports with the SEC as Director of Enpro Inc. (NPO), Director of Tyra Biosciences, Inc. (TYRA) and Director of NewAmsterdam Pharma Co N.V. (NAMS).

Signal8 holds 21 ownership filings by Gulfo Adele M. (2 Form 3, 19 Form 4), filed between Sep 19, 2024 and Sep 17, 2026. Those filings report 25 transactions, from Sep 18, 2024 to Sep 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gulfo Adele M.'s filings is in CHARLOTTE, NC.

Recent filings by Gulfo Adele M.

Sep 16, 2026: Grants or awards of NPO derivative securities (2 lines, Form 4, code A).
Jun 17, 2026: Grants or awards of NPO derivative securities (2 lines, Form 4, code A).
May 28, 2026: Grant or award of TYRA derivative securities (Form 4, code A).
Mar 18, 2026: Grants or awards of NPO derivative securities (2 lines, Form 4, code A).
Feb 12, 2026: Grant or award of NPO shares (Form 4, code A).

Other insiders filing for Enpro Inc. (NPO)

Reinsdorf Judith A, Director
Botts Thomas M., Director
Abbey William, Director
Humphrey John, Director
Brueck Felix M., Director
Bianchi Amy, EVP and CHRO

How to read Form 4 transaction codes